Bitcoin halving
What does that mean?
$2.8T
Total marketcap
$120.41B
Total volume
BTC 49.83%     ETH 15.33%
Dominance

Gilead Sciences, Inc. GILD.BA Stock

19734 ARS {{ price }} -0.676951% {{change_pct}}%
COUNTRY
Argentina
Market Cap
77.93T ARS
LOW - HIGH [24H]
19627.5 - 20151.5 ARS
VOLUME [24H]
220 ARS
{{ volume }}
P/E Ratio
5.11
Earnings per share
3856.02 ARS

Gilead Sciences, Inc. Price Chart

Gilead Sciences, Inc. GILD.BA Financial and Trading Overview

Gilead Sciences, Inc. stock price 19734 ARS
Previous Close 9770.5 ARS
Open 9850 ARS
Bid 9915 ARS x N/A
Ask 9990 ARS x N/A
Day's Range 9798.5 - 9990 ARS
52 Week Range 3549.5 - 10453 ARS
Volume 179 ARS
Avg. Volume 361 ARS
Market Cap 24.51T ARS
Beta (5Y Monthly) 0.40669
PE Ratio (TTM) 9.188773
EPS (TTM) 3856.02 ARS
Forward Dividend & Yield 156.22 (1.59%)
Ex-Dividend Date March 14, 2023
1y Target Est N/A

GILD.BA Valuation Measures

Enterprise Value 12.21T ARS
Trailing P/E 9.188773
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 906.2882
Price/Book (mrq) 592.3031
Enterprise Value/Revenue 451.352
Enterprise Value/EBITDA 979.687

Trading Information

Gilead Sciences, Inc. Stock Price History

Beta (5Y Monthly) 0.40669
52-Week Change 169.08%
S&P500 52-Week Change 20.43%
52 Week High 10453 ARS
52 Week Low 3549.5 ARS
50-Day Moving Average 9270.61 ARS
200-Day Moving Average 7348.65 ARS

GILD.BA Share Statistics

Avg. Volume (3 month) 361 ARS
Avg. Daily Volume (10-Days) 235 ARS
Shares Outstanding 1.25B
Float 1.25B
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 0%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 2.94
Trailing Annual Dividend Yield 0.030%
5 Year Average Dividend Yield N/A
Payout Ratio 0.1663
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 20.64%
Operating Margin (ttm) 37.86%
Gross Margin 79.16%
EBITDA Margin 46.07%

Management Effectiveness

Return on Assets (ttm) 10.24%
Return on Equity (ttm) 27.11%

Income Statement

Revenue (ttm) 27.04B ARS
Revenue Per Share (ttm) 21.58 ARS
Quarterly Revenue Growth (yoy) -3.59%
Gross Profit (ttm) 21.62B ARS
EBITDA 12.46B ARS
Net Income Avi to Common (ttm) 5.58B ARS
Diluted EPS (ttm) 1084.53
Quarterly Earnings Growth (yoy) 5215.80%

Balance Sheet

Total Cash (mrq) 6.52B ARS
Total Cash Per Share (mrq) 5.23 ARS
Total Debt (mrq) 25.24B ARS
Total Debt/Equity (mrq) 120.54 ARS
Current Ratio (mrq) 1.278
Book Value Per Share (mrq) 16.825

Cash Flow Statement

Operating Cash Flow (ttm) 8.98B ARS
Levered Free Cash Flow (ttm) 8.51B ARS

Profile of Gilead Sciences, Inc.

Country Argentina
State CA
City Foster City
Address 333 Lakeside Drive
ZIP 94404
Phone 650 574 3000
Website https://www.gilead.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 17000

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Q&A For Gilead Sciences, Inc. Stock

What is a current GILD.BA stock price?

Gilead Sciences, Inc. GILD.BA stock price today per share is 19734 ARS.

How to purchase Gilead Sciences, Inc. stock?

You can buy GILD.BA shares on the Buenos Aires exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Gilead Sciences, Inc.?

The stock symbol or ticker of Gilead Sciences, Inc. is GILD.BA.

Which industry does the Gilead Sciences, Inc. company belong to?

The Gilead Sciences, Inc. industry is Drug Manufacturers-General.

How many shares does Gilead Sciences, Inc. have in circulation?

The max supply of Gilead Sciences, Inc. shares is 3.95B.

What is Gilead Sciences, Inc. Price to Earnings Ratio (PE Ratio)?

Gilead Sciences, Inc. PE Ratio is 5.11771200 now.

What was Gilead Sciences, Inc. earnings per share over the trailing 12 months (TTM)?

Gilead Sciences, Inc. EPS is 3856.02 ARS over the trailing 12 months.

Which sector does the Gilead Sciences, Inc. company belong to?

The Gilead Sciences, Inc. sector is Healthcare.